Atara Biotherapeutics, Inc.ATRANASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank23
3Y CAGR-48.2%
5Y CAGR-31.1%
Year-over-Year Change
Research and development spending
3Y CAGR
-48.2%/yr
vs +12.9%/yr prior
5Y CAGR
-31.1%/yr
Recent deceleration
Acceleration
-61.1pp
Decelerating
Percentile
P23
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
4 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $37.89M | -75.0% |
| 2024 | $151.48M | -32.6% |
| 2023 | $224.78M | -17.5% |
| 2022 | $272.53M | -3.4% |
| 2021 | $282.00M | +15.3% |
| 2020 | $244.65M | +13.2% |
| 2019 | $216.10M | +29.0% |
| 2018 | $167.46M | +106.2% |
| 2017 | $81.21M | +43.7% |
| 2016 | $56.51M | - |